MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

drug therapy

  • Home
  • drug therapy
Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles
Posted inCardiology Specialties

Catheter Ablation vs Drug Therapy for Atrial Fibrillation: Insights from the CABANA Trial by Nonmodifiable Risk Profiles

Posted by By MedXY 09/11/2025
This secondary analysis of the CABANA trial reveals catheter ablation significantly benefits AF patients with fewer than three nonmodifiable recurrence risk factors, underscoring the potential for personalized treatment strategies.
Read More
  • Remote Aerobic Exercise Accelerates Recovery in Youth with Prolonged Concussion: Insights from the MSTEP Randomized Trial
  • Evaluating Reduced Versus Standard Dosing of Janus Kinase Inhibitors in Rheumatoid Arthritis: Insights from a Propensity Score-Matched Real-World Study
  • Optimizing Early Mycophenolate Mofetil Dosing Post-Kidney Transplant: A Nomogram Integrating Triglycerides and Body Weight
  • Non-Attendance in Exercise Therapy Among Multimorbid Patients: Insights from the MOBILIZE Trial
  • International Consensus on Low‑Dose Oral Minoxidil in Children: Practical, Pediatric‑Specific Guidance
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top